FDA submits proposed peptide “interim access” policy to White House for review, The Hill reports

The Food and Drug Administration has submitted a proposed peptide “interim access policy” to the White House for review, according to a government filing described by The Hill in a report published October 15. The reported submission is part of a policy track aimed at allowing certain compounding pharmacies to temporarily produce and sell previously restricted peptide products, subject to the terms of the draft policy and any further White House review.

The Hill report ties the effort to the administration’s broader healthcare policy agenda advanced by advocates associated with RFK Jr., though the specific role of any individual or office is not fully detailed in the description. The report characterizes the step as an FDA action that would determine whether and how the agency would move forward with a regulatory approach for peptides through an interim access mechanism while longer-term pathways remain under development.

According to The Hill, the FDA’s draft policy would focus on “compounding pharmacies” and an “interim access” approach, suggesting a time-limited regulatory allowance rather than a permanent change. The report also describes the peptide products involved as “previously restricted,” indicating that the proposed policy is intended to modify access conditions for at least some categories of peptides that were not broadly available under existing rules.

The FDA’s decision to send the draft to the White House indicates the policy is moving through an interagency or executive-branch review process rather than being finalized solely within the agency. While the report does not provide the full text of the draft policy in its summary, it frames the White House review as the next procedural step before any potential implementation by the agency.

Regulatory changes to drug compounding and product availability can have practical effects on compliance expectations for pharmacies, the scope of what products can be prepared and sold, and the oversight structure for quality and safety. In this case, the reported interim nature of the proposal also implies that the agency and the administration may be weighing near-term access against ongoing enforcement and regulatory constraints that previously limited access to the relevant peptide products.

Opposition framing is also expected in disputes over FDA access policies, particularly where compounding authorities and previously restricted drug categories intersect. However, The Hill’s summary, as provided here, does not specify which organizations are opposing the approach or what their legal or technical arguments are. A definitive assessment will depend on the final policy text, any accompanying legal justification, and the official publication of the FDA’s decision or related executive-branch materials.

A key next step will be whether the White House completes its review and returns any required edits or directs FDA to proceed. If FDA moves forward, the policy would likely be accompanied by official regulatory documents or guidance that spell out eligibility, permitted activities, and compliance requirements for affected compounding pharmacies. As of now, no White House or Federal Register confirmation of the specific FDA submission has been verified in the provided research records.